Search
Search Results
-
Immune Checkpoint Inhibitors in Oncology
In this chapter, we explore the evolution and current state of immune checkpoint inhibitors (ICIs) in cancer treatment, focusing on their mechanism...
-
Immune Checkpoint Inhibitors in Urological Cancers
Over-expression of the immune checkpoint inhibitors is an important approach for malignant cells to escape the host immune system; therefore, the use...
-
Immune Checkpoint Blockade Response Biomarkers
Cancer immunotherapy based on immune checkpoint blockade (ICB) has demonstrated durable clinical benefit in patients with immunogenic tumors,...
-
Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment
Due to improved understanding of the tumor biology and immunology, cancer immunotherapy has rapidly developed as a promising strategy to treat...
-
Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment
Lung cancer is the leading cause of cancer-related fatalities worldwide in both men and women. Targeted therapy and chemotherapy have enhanced lung...
-
Phosphatidylserine externalization as immune checkpoint in cancer
Cancer is the second leading cause of mortality worldwide. Despite recent advances in cancer treatment including immunotherapy with immune checkpoint...
-
Diagnosis and Management of Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
The landscape of cancer therapy has undergone a profound transformation in the last decade, shifting from traditional cytotoxic chemotherapy to the...
-
Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy
Immune checkpoint inhibitors (ICIs) are a novel drug category enhancing the patient’s immune response against tumors. Their approval in cancer...
-
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs....
-
PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer
Gallbladder cancer (GBC) is an aggressive cancer with poor prognosis. PARP inhibitors (PARPi) target PARP enzymes and have shown efficacy in patients...
-
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may...
-
Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients
BackgroundImbalanced immune responses are involved in develo** preeclampsia (PE). We wish to explore the expression and potential changes of immune...
-
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
The circadian clock is a critical regulator of immunity, and this circadian control of immune modulation has an essential function in host defense...
-
Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy
Cancer immunotherapy, especially immune checkpoint therapy, has revolutionized therapeutic options by reactivating the host immune system. However,...
-
HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy
Background: The distribution of human leukocyte antigen-G (HLA-G) is limited in physiological situations. Functionally, HLA-G is an important...
-
Tumor stroma-derived ANGPTL2 potentiates immune checkpoint inhibitor efficacy
Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic. We recently reported that tumor stroma-derived...
-
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Although more than a decade has passed since the approval of immune checkpoint inhibitors (ICIs) for the treatment of melanoma and non-small-cell...
-
Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer
BackgroundThe efficacy of anti-PD-1 therapy is primarily hindered by the limited T-cell immune response rate and immune evasion capacity of tumor...
-
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study
BackgroundCheckpoint inhibitors (CPIs) are widely used in cancer treatment, with transformative impacts on survival. They nonetheless carry a...
-
Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial–Mesenchymal Transition
Immune checkpoint blockade therapies have generated efficacious responses in certain tumor types; however, the responses of breast carcinomas have...
